FY2027 EPS Estimates for NovoCure Reduced by HC Wainwright

NovoCure Limited (NASDAQ:NVCR) – Stock analysts at HC Wainwright decreased their FY2027 earnings per share (EPS) estimates for shares of NovoCure in a report released on Thursday, June 18th. HC Wainwright analyst E. Bodnar now anticipates that the medical equipment provider will post earnings of ($1.22) per share for the year, down from their previous estimate of ($1.07). HC Wainwright currently has a “Buy” rating and a $46.00 target price on the stock. The consensus estimate for NovoCure’s current full-year earnings is ($1.55) per share. HC Wainwright also issued estimates for NovoCure’s FY2028 earnings at ($0.46) EPS.

NovoCure (NASDAQ:NVCR) last issued its quarterly earnings results on Thursday, April 30th. The medical equipment provider reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). The company had revenue of $174.06 million during the quarter, compared to the consensus estimate of $167.77 million. NovoCure had a negative return on equity of 50.82% and a negative net margin of 25.66%.The firm’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.31) earnings per share.

NVCR has been the topic of a number of other reports. Evercore reissued an “outperform” rating on shares of NovoCure in a research report on Friday, May 1st. Weiss Ratings raised NovoCure from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 1st. Wedbush reiterated a “neutral” rating and issued a $18.00 price target on shares of NovoCure in a report on Thursday, April 16th. Finally, Wells Fargo & Company raised their price target on NovoCure from $13.50 to $17.00 and gave the stock an “equal weight” rating in a research note on Monday, May 4th. Four equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, NovoCure currently has a consensus rating of “Hold” and a consensus target price of $26.86.

NovoCure Price Performance

NovoCure stock opened at $14.28 on Monday. NovoCure has a 12-month low of $9.82 and a 12-month high of $18.92. The company has a current ratio of 2.90, a quick ratio of 2.70 and a debt-to-equity ratio of 0.71. The firm has a 50-day moving average price of $15.60 and a 200-day moving average price of $13.56. The firm has a market capitalization of $1.65 billion, a PE ratio of -9.33 and a beta of 0.93.

Insider Buying and Selling at NovoCure

In related news, Director W Anthony Vernon sold 2,945 shares of the firm’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $15.77, for a total transaction of $46,442.65. Following the sale, the director owned 197,657 shares of the company’s stock, valued at $3,117,050.89. This trade represents a 1.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeryl L. Hilleman sold 2,945 shares of the firm’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $15.77, for a total transaction of $46,442.65. Following the completion of the sale, the director owned 13,861 shares in the company, valued at $218,587.97. This represents a 17.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 51,943 shares of company stock worth $893,171. 5.52% of the stock is currently owned by company insiders.

Institutional Trading of NovoCure

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Empowered Funds LLC acquired a new stake in shares of NovoCure in the 4th quarter worth $33,000. Kestra Advisory Services LLC acquired a new position in NovoCure during the 4th quarter valued at about $49,000. Larson Financial Group LLC raised its stake in NovoCure by 662.1% in the third quarter. Larson Financial Group LLC now owns 4,100 shares of the medical equipment provider’s stock valued at $53,000 after buying an additional 3,562 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in NovoCure by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,442 shares of the medical equipment provider’s stock valued at $70,000 after buying an additional 1,120 shares during the last quarter. Finally, Acadian Asset Management LLC acquired a new stake in NovoCure in the first quarter worth about $87,000. Hedge funds and other institutional investors own 84.61% of the company’s stock.

Key Stories Impacting NovoCure

Here are the key news stories impacting NovoCure this week:

• Negative Sentiment: NovoCure’s Phase 3 TRIDENT trial missed its primary survival endpoint in newly diagnosed glioblastoma, undermining the commercial prospects for its cancer treatment platform. Reuters article
• Negative Sentiment: A lawsuit/investigation notice followed the trial miss, signaling potential legal and governance risk after the stock’s steep decline. PR Newswire article
• Neutral Sentiment: HC Wainwright reiterated a Buy rating and a $46 price target, though it trimmed FY2029 and FY2030 earnings estimates slightly, suggesting long-term optimism remains but near-term expectations were nudged lower.

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.